Investigating the Association between the Autophagy Markers LC3B, SQSTM1/p62, and DRAM and Autophagy-Related Genes in Glioma
-
Published:2024-01-01
Issue:1
Volume:25
Page:572
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Danish Farheen1, Qureshi Muhammad Asif1ORCID, Mirza Talat2, Amin Wajiha3, Sufiyan Sufiyan3, Naeem Sana3, Arshad Fatima1, Mughal Nouman3
Affiliation:
1. Department of Pathology, Dow International Medical College, Dow University of Health Sciences, Karachi 75300, Pakistan 2. Departments of Research & Molecular Medicine, Ziauddin University, Karachi 75600, Pakistan 3. Departments of Biological and Biomedical Sciences, Aga Khan University, Karachi 74800, Pakistan
Abstract
High-grade gliomas are extremely fatal tumors, marked by severe hypoxia and therapeutic resistance. Autophagy is a cellular degradative process that can be activated by hypoxia, ultimately resulting in tumor advancement and chemo-resistance. Our study aimed to examine the link between autophagy markers’ expression in low-grade gliomas (LGGs) and high-grade gliomas (HGGs). In 39 glioma cases, we assessed the protein expression of autophagy markers LC3B, SQSTM1/p62, and DRAM by immunohistochemistry (IHC) and the mRNA expression of the autophagy genes PTEN, PI3K, AKT, mTOR, ULK1, ULK2, UVRAG, Beclin 1, and VPS34 using RT-qPCR. LC3B, SQSTM1/p62, and DRAM expression were positive in 64.1%, 51.3%, and 28.2% of glioma cases, respectively. The expression of LC3B and SQSTM1/p62 was notably higher in HGGs compared to LGGs. VPS34 exhibited a significant differential expression, displaying increased fold change in HGGs compared to LGGs. Additionally, it exhibited robust positive associations with Beclin1 (rs = 0.768), UVRAG (rs = 0.802), and ULK2 (rs = 0.786) in HGGs. This underscores a potential association between autophagy and the progression of gliomas. We provide preliminary data for the functional analysis of autophagy using a cell culture model and to identify potential targets for therapeutic interventions.
Reference55 articles.
1. Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., and Bray, F. (2013). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. 2. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013;Ostrom;Neuro-Oncol.,2016 3. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019;Ostrom;Neuro-Oncol.,2022 4. The 2021 WHO classification of tumors of the central nervous system: A summary;Louis;Neuro-Oncol.,2021 5. Epidemiology of brain tumors;Fisher;Neurol. Clin.,2007
|
|